Background {#Sec1}
==========

Colorectal cancer is a serious threat to human health. Mid-low rectal cancer accounts for 70% of colorectal cancer \[[@CR1], [@CR2]\]. Radical surgery (RS) remains the main treatment for mid-low rectal cancer \[[@CR3], [@CR4]\]. However, 10--20% of patients still have local recurrence after radical surgery \[[@CR5], [@CR6]\]. Neoadjuvant chemoradiotherapy has reduced the local recurrence rate of patients and can preserve the anus. Approximately 20% of rectal cancer patients have a good response to neoadjuvant chemoradiotherapy (NCRT). If NCRT (50.4 Gy/25 and capecitabine) is performed, surgery should be extended approximately 6--12 weeks. The tumor can shrink to a minimum size and even disappear completely after neoadjuvant chemoradiotherapy \[[@CR7]\]. Approximately 10--20% of patients can achieve a clinical complete response (cCR) \[[@CR8]\]. The stringent definition of cCR was proposed by Mass in 2012, and it contained five diagnostic criteria \[[@CR9]\]. The diagnostic criteria of cCR were no residual tumor and white scar in endoscopy, negative biopsies from the white scar, no palpable tumor with digital rectal exam (DRE), no suspicious lymph nodes in MRI, and substantial downsizing with no residual tumor or residual fibrosis in MRI \[[@CR10]\]. In our opinion, the most critical points in adopting the wait and see strategy (WS) strategy are no residual tumor in endoscopy and no suspicious lymph nodes or residual tumor in MRI.

In 2004, Habr-Gama published the results of rectal cancer patients with cCR status after neoadjuvant chemoradiotherapy. Habr-Gama first proposed the WS strategy of treating rectal cancer patients with cCR status and pointed out that the WS strategy could achieve similar clinical effects as surgery \[[@CR11]\]. The 5-year DFS and OS rates of cCR status were 92% and 100%, respectively. The 5-year disease-free and 5-year overall survival rates of the radical surgery group were 83% and 88%, respectively. No significant differences were found between the two groups. Nowadays, there are three routine treatments for patients with cCR status: they are WS strategy, radical surgery, and local resection. WS strategy has no invasive operations to the tumor, no surgical trauma, and no change in intestinal function, which ensures the good quality of life of patients. Radical surgery mainly follow the total mesorectal excision (TME) principle, where it needs to remove 15 cm bowel from the upper edge of the tumor and 3--5 cm from the lower edge, with the corresponding lymph nodes. After radical surgery, there may be some changes in bowel function with increased stool frequency and decreased sexual function. And some patients may have loose anus. It could bring physical and psychological trauma to the patients. Local excision only cut off the tumor and the surrounding normal tissues to ensure negative margins, and it could ensure the continuity of the intestine and would not have a significant impact on bowel function and quality of life. The details of specific resection range are in additional file [8](#MOESM8){ref-type="media"}.

There were several meta-analyses related to this topic, such as Li's research, Dossa's research, and some other papers published in a Chinese magazine \[[@CR12]--[@CR14]\]. The disease-free survival (HR 0.56, 95% CI 0.20--1.60) and overall survival (HR 3.91, 95% CI 0.57--26.72) of Dossa's research are similar to those of Li. Our study included more studies and more patients to explore the efficacy and safety of the wait and see strategy versus those of surgery for rectal cancer with cCR response after neoadjuvant chemoradiotherapy. We also performed a meta-analysis to compare the efficacy and safety of the WS strategy versus those of radical surgery and those of WS strategy versus those of local resection (LE).

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

We carried out this meta-analysis by using the PRISMA guidelines. The details of PICOS were as follows: Population: rectal cancer patients with a cCR response after neoadjuvant chemoradiotherapy; Intervention: wait and see strategy; Comparator: radical surgery or local excision; Outcomes: long-term outcomes including local recurrence, distant metastasis, cancer-related death, disease-free survival (DFS), and overall survival (OS) which were analyzed and compared (additional file [3](#MOESM3){ref-type="media"}). Continuous data were evaluated by the standardized mean differences (SMD) with 95% confidence intervals (95% CIs), and dichotomous outcomes were evaluated by relative risks (ORs or RRs) with 95% CIs.

We searched the Cochrane Library, PubMed, CNKI (China National Knowledge Infrastructure), and Wanfang databases (up to March 2020). Articles about wait and see versus radical surgery or local excision after neoadjuvant chemoradiotherapy for rectal cancer were collected. To avoid missing useful articles, we expanded the scope of search terms and find articles for the purpose by manual screening. The search terms were "wait and see" or "nonoperative management" and "neoadjuvant chemoradiotherapy" and "rectal cancer." The details are shown in additional file [1](#MOESM1){ref-type="media"}.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

There were 4 inclusion criteria: (1) pathological and long-term outcomes were compared between wait and see and radical surgery or local excision for rectal cancer with cCR response after neoadjuvant chemoradiotherapy; (2) surgery included radical surgery and local excision; (3) cCR response after neoadjuvant chemoradiotherapy (criteria for ccR were mentioned above) \[[@CR15]\]; and (4) RCT (randomized Controlled Trial), RCNTs (retrospective comparative non-randomized studies), PCNTs (prospective comparative non-randomized studies), cohort studies, or case-control studies. The details of diagnostic criteria of all studies are shown in Table [1](#Tab1){ref-type="table"}. The details of diagnostic criteria of each method in each study are shown in additional file [2](#MOESM2){ref-type="media"}. Table 1Characteristics of the included articlesStudyYearCountryCaseAgeQuality controlDiagnostic criteriaStudy designNeoadjuvant therapyEvaluationFollow-up time (month)Radical surgery typeNOS scoreWSRSLEWSRSLESelectionComparabilityOutcomeTime (week)WSRSLEAPR or LARAyloor \[[@CR16]\]2013India2310--5055--321➀➁➂+ CT, ultrasoundRNCTLong-range radiotherapy4--67272--APR or LAR6Dalton \[[@CR17]\]2012UK66--6869--322➀➁➃➄PNCTCape/45--50.4Gy6--825.339.3--TME7Habr \[[@CR11]\]2004Brazil7122--58.153.6--231➀➁➂+CTPNCT5-FU+LV/45--50.4Gy6--857.348--TME6Lai \[[@CR18]\]2016Taiwan1826--67.563.7--222➀➃➄RNCT5-FU/45--50.4Gy8--124942--APR or LAR orLAR+ loop stoma6Lee \[[@CR19]\]2015Korea82816647070321➂➃➄PNCT50.4Gy6--10414141TME6Li \[[@CR20]\]2015China3092--6256--312➀➁➂➃➄PNCTCape/50;25Gy8--105858--APR or LAR6Mass \[[@CR21]\]2011Netherlands2120--6566--322➀➁➂➃➄PNCTCape/45Gy6--82535--TME7Renehan \[[@CR22]\]2016UK129109--66.965--232➀➁➂➃➄PNCT5-FU/45Gy83333--TME7Smith \[[@CR23]\]2012USA3257--7060--331➀➁➂➃➄PNCT5-FU+ Cape/50.4Gy4--102843----7Yeom \[[@CR24]\]2019Korea15129257464.873232➀➁➂➃➄RNCTCape /50.4Gy or Capeox/50.4Gy or 5-FU /50.4Gy8606060TME7Wang \[[@CR25]\]2020China59179--5857--222➀➁➂➃➄RNCT5-FU+ Cape/50.4Gy6--126060--TME6Notes: *PNCT* prospective non-randomized controlled trial, *RNCT* retrospective non-randomized controlled trial, *5-FU* 5-fluorouracil, *Cape* capecitabine, *RS* radical surgery, *TME* total mesorectal excision, *APR* abdomi-l-perineal resection, *LAR* low anterior resectionDiagnostic criteria of cCR: ➀ no residual tumor and white scar in endoscopy, ➁ negative biopsies from the white scar, ➂ no palpable tumor with digital rectal exam (DRE), ➃ no suspicious lymph nodes in MRI, and ➄ no residual tumor or residual fibrosis in MRI

There were 3 exclusion criteria: (1) studies with no valuable outcome; (2) patients were not well grouped or groups were confusing and not suitable for the purpose of the article; and (3) bad clinical response of rectal cancer after neoadjuvant chemoradiotherapy. Bad clinical response included larger residual tumor in endoscopy and DRE, positive biopsies, and larger tumor and lymph nodes in MRI. The details of inclusion and exclusion criteria are in additional file [6](#MOESM6){ref-type="media"}.

Data extraction and quality control {#Sec5}
-----------------------------------

Using the Newcastle-Ottawa Scale (NOS) guidelines, two reviewers searched the literatures (GHZ and DMY) independently \[[@CR26]\]. We collected the useful data, as shown in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, and [4](#Tab4){ref-type="table"}. Table [1](#Tab1){ref-type="table"} contains the baseline data of related studies. Table [2](#Tab2){ref-type="table"} contains the initial tumor stages of the included patients. Table [3](#Tab3){ref-type="table"} contains the tumor staging after including neoadjuvant therapy. Table [4](#Tab4){ref-type="table"} contains the primary and secondary objectives. The primary objectives include local recurrence (LE), distant metastasis (DM), and cancer-related death (CRD). The secondary objectives include disease-free survival (DFS) and overall survival (OS). More basic information of patients and the details of neoadjuvant treatment plans are in additional file [4](#MOESM4){ref-type="media"} and additional file [5](#MOESM5){ref-type="media"}. A third reviewer had the final decision power to resolve the disagreements of the study. We tried to contact the authors with missing data, but did not get any relevant data. Table 2T stage, N stage and clinical stage of the included articlesStudyT stage (*n*; %)N stage (*n*; %)T1--T2T3--T4N0N1--N2WSRSLEWSRSLEWSRSLEWSRSLEAyloor \[[@CR16]\]94--146--------------Dalton \[[@CR17]\]1----56--1----56--Habr \[[@CR11]\]141--5721--5516--166--Lai \[[@CR18]\]------------------------Lee \[[@CR19]\]5673229513143152Li \[[@CR20]\]824--2268--1439--1653--Mass \[[@CR21]\]61--1519--63--1517--Renehan \[[@CR22]\]3124--9885--4547--84181--Smith \[[@CR23]\]1011--2239--1420--1831--Yeom \[[@CR24]\]38212121235751910546Wang \[[@CR25]\]68--53171--1447--45132--Total93(23.6)87(13.3)9(21.9)301(76.3)558(85.5)32(78.1)159(42.8)260(34.4)33(80.4)212(57.2)495(65.5)8(19.6)Clinical stage (*n*; %)IIIIIIIVWSRSLEWSRSLEWSRSLEWSRSLE------------------------------------------------------------------------------118718---------------------------------------------------------------------------------------------------------82--618--1831--------------------------------------------------------8 (16)2 (2.5)--17 (34)26 (33.7)--25 (50)49 (63.8)--------Table 3Pathologic staging and subtypes of included articles after radiotherapyStudyPathologic T stage (*n*; %)Pathologic N stage (*n*; %)ypT0ypT1ypT2ypT3ypT4ypN0ypN1--2RSLERSLERSLERSLERSLERSLERSLEAyloor \[[@CR16]\]6------3--1------6--5--Dalton \[[@CR17]\]----------------------------Habr \[[@CR11]\]----------------------------Lai \[[@CR18]\]----------------------------Lee \[[@CR19]\]1362694400024--4--Li \[[@CR20]\]----------------------Mass \[[@CR21]\]----------------------Renehan \[[@CR22]\]----------------------Smith \[[@CR23]\]----------------------Yeom \[[@CR24]\]46124711----362----108--21--Wang \[[@CR25]\]----------------------Total65 (38.9)18 (43.9)49 (29.3)17 (41.4)12 (7.1)4 (9.7)41 (24.7)2 (5)00138 (82.1)30 (17.9)--Pathologic subtypesWell differentiatedModerate differentiatedPoorly differentiatedUnknownWSRSWSRSWSRSWSRS----------------------------------------------------------------------------------------------------------------515861042143695--------------------------------22945126201024Table 4Characteristics of the included articlesStudyLR (*n*/%)DM (*n*/%)CRD (*n*/%)WSRSLEWSRSLEWSRSLEAyloor \[[@CR16]\]70--32--------Dalton \[[@CR17]\]------------------Habr \[[@CR11]\]20--33--02--Lai \[[@CR18]\]20--01--------Lee \[[@CR19]\]216032------Li \[[@CR20]\]22--15--04--Mass \[[@CR21]\]10--01--------Renehan \[[@CR22]\]------------------Smith \[[@CR23]\]60--33--10--Yeom \[[@CR24]\]6155454------Wang \[[@CR25]\]71--617--------Total35 (12.6)19 (3.3)11 (26.8)20 (7.2)40 (7.1)6 (14.6)1 (0.7)6 (3.5)--2-year OS (*n*/%)2-year DFS (*n*/%)5-year OS (*n*/%)5-year DFS (*n*/%)WSRSLEWSRSLEWSRSLEWSRSLE------------------------66--66--------------7120--7019--7120--6819--1826--------1824--------------62510------------3092--2991--3088--2785--2119--1919--------------107100--10089--------------3157--2856--------------------------3128--3110--------------53175--------284 (92.5)320 (96.3)--258 (86.8)305 (91.3)10 (62.5)175 (90.6)435 (97.0)--98 (84.4)214 (88.0)--Notes: *LR* local recurrence, *DM* distant metastasis, *CRD* cancer-related death, *DFS* disease-free survival, *OS* overall survival

Statistical analysis {#Sec6}
--------------------

We used RevMan 5.0 to carry out the meta-analysis. Continuous data were evaluated by the standardized mean differences (SMD) with 95% confidence intervals (95% CIs), and dichotomous data were evaluated by relative risks (ORs or RRs) with 95% CIs. Heterogeneity and publication bias were estimated by *I*^2^ statistic and funnel plots separately. When huge heterogeneity existed (*I*^2^≧50%), we used random-effects models to analyze the data. We used fixed-effects model to analyze the data with little heterogeneity (*I*^2^ \< 50%).

Results {#Sec7}
=======

Study selection {#Sec8}
---------------

Duplicated records were deleted. We deleted 1843 studies after reading the titles and abstracts carefully. Deleted studies were due to not of rectal cancer (*n* = 527), no control group (*n* = 851), and insufficient data (*n* = 455). Regarding study information, after we read the remaining studies carefully, 11 English studies with 1131 patients were included \[[@CR11], [@CR16]--[@CR25]\]. There were 412 patients in the WS group, 678 patients in the RS group, and 41 patients in the LE group. There were 6 Eastern studies and 5 Western studies in the meta-analysis. There were 10 English studies, and 1 was a Chinese study. The Western research included European, American, and Latin American research, while the Eastern research mainly included Asian research. Yeom and Lai reported local resection for rectal cancer with cCR response after neoadjuvant chemoradiotherapy. Some baseline data from the articles were inconsistent, which could affect the results. We deleted several articles and hoped to reduce the bias caused by inconsistent baseline data. Patient information: the clinical stages of included patients were stages I to III. Approximately 81.9% of patients were at the beginning T3--4 and 67.8% N1--2 (Table [2](#Tab2){ref-type="table"}). A total of 19.4% of patients were ypT3--T4 and 11.8% of patients were ypN1--2, and we divided the surgery group into RS (radical surgery) and LE (local excision). The clinical staging of included articles after neoadjuvant chemoradiotherapy is shown in Table [3](#Tab3){ref-type="table"}. The long-term outcomes are shown in Table [4](#Tab4){ref-type="table"}. The long-term outcomes included local recurrence, distant metastasis, cancer-related death, disease-free survival, and overall survival (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Flowchart of the included studies

Quality assessment {#Sec9}
------------------

We evaluated the quality of the included studies using the NOS assessment scale (Newcastle-Ottawa Quality Assessment Scale). The score indicated three levels of quality: low (1--3), moderate (4--6), and high (7--9). We included 11 studies in our study (4 RCNT and 7 prospective non-randomized controlled trial (PNCT)) with moderate to high quality. No relevant RCTs were found during the database search. The details are shown in Table [1](#Tab1){ref-type="table"}.

Primary objectives {#Sec10}
==================

WS group versus RS group {#Sec11}
------------------------

### Local recurrence, distant metastasis, and cancer-related death {#Sec12}

The WS group had a higher recurrence rate than the RS group. Other primary objectives were similar in the two groups. The details were as follows: 9 studies reported clinical data on local recurrence, and the WS group had a higher recurrence rate than the RS group in the fixed-effects model (OR 7.32, 95% CI 3.58 to 14.95, *P* \< 0.001, chi^2^ = 4.51, *P* = 0.81, *I*^2^ = 0%, Fig. [2](#Fig2){ref-type="fig"}a). Western studies (OR 7.22, 95% CI 1.36 to 38.37, *P* = 0.02, chi^2^ = 2.03, *P* = 0.36, *I*^2^ = 1%, Fig. [2](#Fig2){ref-type="fig"}a), and Eastern studies (OR 5.57, 95% CI 2.36 to 13.15, *P* \< 0.001, chi^2^ = 0.69, *P* = 0.95, *I*^2^ = 0%, Fig. [2](#Fig2){ref-type="fig"}a) had the same results in local recurrence. The WS group had a similar distant metastasis rate as the radical surgery group in the fixed-effects model with high heterogeneity (OR 1.03, 95% CI 0.59 to 1.81, *P* = 0.92, chi^2^ = 13.01, *P* = 0.11, *I*^2^ = 38%, Fig. [2](#Fig2){ref-type="fig"}b). The occurrence of cancer-related death (OR 0.44, 95% CI 0.12 to 1.60, *P* = 0.22, chi^2^ = 4.07, *P* = 0.25, *I*^2^ = 26%, Fig. [2](#Fig2){ref-type="fig"}c) was similar between the two groups in the fixed-effects model with little heterogeneity. Fig. 2Outcomes of WS group versus Radical surgery group. **a** local recurrence, **b** distant metastasis, and **c** cancer-related death

WS group versus LE group {#Sec13}
------------------------

### Distant metastasis and local recurrence {#Sec14}

The primary objectives were similar in the two groups. Similar distant metastasis rates were found in the two groups in the fixed-effects model with little heterogeneity (OR 1.24, 95% CI 0.33 to 4.69, *P* = 0.75, chi^2^ = 0.94, *P* = 0.33, *I*^2^ = 0%, Fig. [3](#Fig3){ref-type="fig"}a). Two studies reported clinical data on local recurrence, which was similar in the two groups in the fixed-effects model (OR 1.46, 95% CI 0.49 to 4.35, *P* = 0.50, chi^2^ = 1.69, *P* = 0.19, *I*^2^ = 41%, Fig. [3](#Fig3){ref-type="fig"}b). Fig. 3Outcomes of WS group versus local excision group. **a** distant metastasis and **b** local recurrence

Secondary objectives {#Sec15}
====================

WS group versus RS group {#Sec16}
------------------------

### 2-Year DFS, 2-year OS, 5-year DFS, and 5-year OS {#Sec17}

The secondary objectives were similar in two groups. The details are as follows: seven studies with WS group had similar 2-year DFS as the RS group in the fixed-effects model with little heterogeneity (OR 0.77, 95% CI 0.46 to 1.28, *P* = 0.3, chi^2^ = 9.44, *P* = 0.15, *I*^2^ = 36%, Fig. [4](#Fig4){ref-type="fig"}a). Seven studies that reported OS with WS groups had similar 2-year OS as the surgery group in the fixed-effects model with little heterogeneity (OR 0.75, 95% CI 0.40 to 1.41, *P* = 0.90, chi^2^ = 8.44, *P* = 0.21, *I*^2^ = 29%, Fig. [4](#Fig4){ref-type="fig"}b). The 5-year DFS (OR 0.47, 95% CI 0.04 to 5.90, *P* = 0.56, chi^2^ = 17.59, *P* \< 0.001, *I*^2^ = 89%, Fig. [4](#Fig4){ref-type="fig"}c) and 5-year OS (OR 1.94, 95% CI 0.19 to 19.62, *P* = 0.56, chi^2^ = 10.25, *P* = 0.02, *I*^2^ = 71%, Fig. [4](#Fig4){ref-type="fig"}d) were similar in both groups in the random-effects model. Fig. 4Outcomes of WS group versus radical surgery group. **a** 2-year DFS, **b** 2-year OS, **c** 5-year DFS, and **d** 5-year OS

Publication bias {#Sec18}
----------------

To determine whether the article had publication bias, we used RevMan 5.0 software to test the index of distant metastasis rate of the included literature and obtained a funnel plot. The points were evenly distributed in the funnel plot, indicating no publication bias in the meta-analysis.

Discussion {#Sec19}
==========

Radical surgery of mid-low rectal cancer can bring great trauma to patients, and some patients require removal of their anus \[[@CR27]\], which could result in a serious impact on patients' physical and mental health \[[@CR28]\]. In 2004, Habr-Gama first reported the wait and see (non-surgical) treatment strategy for low rectal cancer patients who obtained cCR after chemoradiotherapy. A total of 71 patients who achieved a cCR status were only closely followed (wait and see) for an average of 57.3 months. Two patients had recurrence in the intestinal lumen, and 3 patients had distant metastasis. The 5-year DFS and OS rates were 92%, and 100% respectively. The other 194 patients without clinical complete response underwent radical surgery. A total of 22 patients had pathologically confirmed pCR (pathologically complete response). The 5-year disease-free survival rate and 5-year overall survival rates were 83% and 88%, respectively. No significant differences were found between the two groups. After expanding the sample size, Habr-Gama got the same conclusion \[[@CR29]\]. Subsequently, many studies about cCR have emerged, and they also confirmed the treatment effect of the wait and see strategy \[[@CR30], [@CR31]\]. Professor Lu found that 50% of cT1--2 tumors could disappear completely, and postoperative pathology was ypT0 \[[@CR32]\]. In addition, as the tumor shrank, local excision surgery and the wait and see strategy were able to ensure organ preservation. Therefore, we aimed to include cCR patients and intended to compare the advantages and disadvantages of the three treatment methods.

Local recurrence, distant metastasis, and cancer-related death {#Sec20}
--------------------------------------------------------------

In this meta-analysis, we found that the WS group had a higher local recurrence rate than the RS group. This result was similar to professor Li's research. Approximately 81.9% of patients were at the beginning T3--4 and 67.8% N1--2 (Table [2](#Tab2){ref-type="table"}). A total of 19.4% of patients were ypT3--T4 and 11.8% of patients were ypN1--2. Patients in whom T stage and N stage were not obviously reduced were prone to relapse after neoadjuvant therapy. Patients could relapse in the WS group easily. However, in the RS surgery group, the recurrence rate was reduced to below 10%. Because few patients had incomplete information in LE group, no significant difference in local recurrence rate was seen in the WS and LE group. We speculated that some patients achieved cCR status in the WS group, but the tumor was not completely cured, so the recurrence rate would increase. But in the surgery group, the tumor has been removed and the recurrence rate can be appropriately reduced. Approximately 7.2% of patients had distant metastasis in the WS group and 7.1% of patients had distant metastasis in the RS group. Fewer studies involved the CRD indicator. There were no significant differences of distant metastasis rate and CRD in three groups. Dossa and Li also arrived at the same result. The wait and see strategy had some advantages, such as reducing surgical trauma, improving the quality of life, and no raising distant metastasis rate.

DFS and OS {#Sec21}
----------

The 2-year DFS rate was 86.8% and 91.3% in the WS and RS groups, respectively. The 2-year OS rates were 92.5% and 96.3% in the WS and RS groups, respectively. The WS group had similar 2-year DFS and OS and 5-year DFS and OS as the RS group. Patients with cCR status were sensitive to neoadjuvant therapy and had good biological behavior, so patients' survival was good in all groups. Due to the huge difference in the baseline data, we deleted Lin's study \[[@CR33]\]. We obtained similar results as Li's research and Dossa's research. Lin's study caused big bias and led to the false result. Arauio and Simth's research included patients with tumor stage IV, so we abandon them \[[@CR34], [@CR35]\]. Currently, doctors use high-sensitivity MRI and colonoscopy to find small tumor lesion and deal with them in time \[[@CR36], [@CR37]\]. The included articles had salvage therapy for patients with local recurrence, which included chemotherapy and surgical treatment. The patients of the WS group, who had not experienced large surgical trauma, had better immunity than surgical group, and they could endure the subsequent treatments.

The specific plan and efficacy of NRCT {#Sec22}
--------------------------------------

The details of the neoadjuvant treatment are shown in additional file [5](#MOESM5){ref-type="media"}. The NCRT of Li's research (50 Gy/25 f/2 Gy, capecitabine, 825 mg/m2 bid, concurrently) had the best clinical effect. This research had the biggest PCR rate and the best DFS/OS rate with long-term radiotherapy and capecitabine. Professor Harb also conducted long-term radiotherapy + 5-fluoracil for neoadjuvant therapy, with a PCR rate of approximately 8.3%. Due to the improvement in the level of radiotherapy and the use of capecitabine sensitizers, the PCR rate was about 20%. At present, the standard neoadjuvant treatment is radiotherapy (45 to 50.4 Gy/25 to 28 f) and capecitabine at 825 mg/m^2^, twice per day (total dose of 1 650 mg/m^2^/d). Surgery should be approximately about 6--8 weeks and 12 weeks at the maximum. In this way, the tumor can shrink to a minimum and the edema of the irradiation field completely disappeared, improving the PCR and anus preservation rate \[[@CR38]\]. The included literature had a long time span, and the neoadjuvant treatment plan was not uniform, which could affect the final result. With the further standardization of neoadjuvant treatment, we hoped more and more studies with the uniform adjuvant treatment plans would appear.

Previous meta-analysis and our update {#Sec23}
-------------------------------------

Although Professor Dossa included 23 studies in his research, only 15 studies had control groups and 5 studies had specific data of comparison between two groups. He proposed that there were no significant differences in non-regrowth recurrence, cancer-specific mortality, overall survival, and disease-free survival. There were 9 studies in Professor Li's research, and he reported that two patient groups were similar in distant metastasis rates, disease-free, and overall survival, but the non-surgical group had a higher risk of 1-, 2-, 3-, and 5-year local recurrence. Our report also showed a higher local recurrence rate in the WS group than the RS group, which affirmed the effect of wait and see strategy for patients with cCR status. Subgroup analysis of Eastern and Western studies were also performed, and we hoped that more studies about cCR-related research of the WS group versus radical surgery or local excision would appear \[[@CR39]\].

Arauio and Smith had patients with Stage IV; thus, we removed those two studies. More cases with T3--4 and N1--2 stage are more needed to perform neoadjuvant treatment than T1--2 and N0 stage. We found that some patients with T3--4 and N1--2 stage could obtain cCR after neoadjuvant treatment with better prognosis than adjuvant treatment. Sometimes, T1--2 and N0 stage might be treated directly with surgery and obtained a considerable effect. However, the relevant prognosis of patients with T and N stage were not specified in the article, and we could not use the meta-analysis to define the specific meaning of T and N stage for cCR. Most patients had achieved T and N stage reduction after neoadjuvant therapy, but there was too little available information to form a conclusion about a specific treatment method for these patients.

Limitations {#Sec24}
===========

This study might have several limitations. First, 11 studies (4 RCNT and 7 PNCT) with a total of 1131 patients could not represent the highest level of evidence due to the non-included RCTs. Second, incomplete clinical data and some unbalanced baseline characteristics could affect the results. Third, differences between Eastern and Western population groups could cause potential selection bias. Finally, more cCR patients need to be included. Furthermore, more RCTs for the wait and see strategy versus surgery for cCR are necessary.

Conclusion {#Sec25}
==========

In summary, this study compared the reliability and safety of the wait and see strategy to radical surgery and local excision for rectal cancer with cCR response after neoadjuvant chemoradiotherapy. The WS group had higher local recurrence rate than the RS group. There was no significant difference in other data. With neoadjuvant chemoradiotherapy development and appropriate salvage therapy for local recurrence, the wait and see strategy could minimize surgical trauma and preserve the anus and had the advantages for cCR patient. Therefore, we propose that the wait and see strategy could be a feasible model for cCR patient.
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